Even before patients are diagnosed with AML, they may carry more mutations in some of these genes (DNMT3A, TET2, TP53, SRSF2, IDH2, SF3B1, JAK2, ASXL1), compared to control individuals and having any of these mutations at baseline assessment can be associated with a statistically significant increased risk of developing AML (27). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.